Galectin Therapeutics (GALT) Total Current Liabilities (2010 - 2026)

Galectin Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $7.3 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 93.41% year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $7.3 million (down 93.41% YoY), while the FY2025 annual figure was $8.0 million, down 77.32% from the prior year.
• Total Current Liabilities was $7.3 million for Q1 2026 at Galectin Therapeutics, down from $8.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $136.4 million in Q3 2025 to a low of $7.3 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $26.6 million across 5 years, with a median of $11.5 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities soared 777.38% in 2025, then tumbled 93.41% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $13.0 million in 2022, then gained by 20.47% to $15.7 million in 2023, then surged by 125.88% to $35.4 million in 2024, then sank by 77.32% to $8.0 million in 2025, then declined by 9.0% to $7.3 million in 2026.
• The last three Total Current Liabilities figures came in at $7.3 million (Q1 2026), $8.0 million (Q4 2025), and $136.4 million (Q3 2025), per Business Quant data.